Liver siRNA is under clinical development by Nitto BioPharma and currently in Phase II for Liver Cancer. According to GlobalData, Phase II drugs for Liver Cancer have a 31% phase transition success ...
In the field of urology, the rising prevalence of diseases such as urinary stones, infections, and cancers poses significant challenges to public health ...
This neglect, combined with inadequate staffing, poor drug availability, and uncompetitive salaries for health workers, paints a bleak picture of what lies ahead for 2025. It is imperative that the ...